Neurocrine Biosciences share price today

Neurocrine Biosciences, Inc.'s share price was $166.05 at the close on 4 November 2026. It has been rising for 1 week. That is 12.4% above its average price over the last 200 trading days. In the last 52 weeks it traded between $124 and $177, and at that close it sat 79% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Neurocrine Biosciences, Inc. is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 1 week in a row.

Over the last 10 years the share price moved +242% while the S&P 500 moved +261%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Neurocrine Biosciences, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

Neurocrine Biosciences is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Neurocrine Biosciences, Inc. earned $144 M of net profit in the Jun 2026 quarter, +34.3% on the same quarter a year earlier. That is the 5th quarter in a row of profit growth. Full-year FY25 profit was $479 M. Over 4 years profit has grown 52.0% a year on average. That is 15.1% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned $108 M.

For the full year, FY25 profit was $479 M (+40.2% on the year before).

Why profit moved: revenue changed +39.5% on a year earlier and the margin moved +1.0 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +637.5% and revenue +34.5%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra dollar of revenue adds more to profit.

Neurocrine Biosciences, Inc. reported $959 M of revenue in the Jun 2026 quarter, +39.5% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 26.0% a year on average. The last full year, FY25, came in at $2.9 B.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to $3.4 B.

FY25 revenue was $2.9 B, +21.4% on the year before.

Recent pace: the last four quarters grew +34.5% on average, against 26.0% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +34.4%, against +26.2% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +102.6%, against +44.2% a year (accelerating).

Neurocrine Biosciences, Inc.'s operating margin was 22.2% in the Jun 2026 quarter, 1.0 percentage points higher than the same quarter a year ago. Across 5 years it has been between 16.7% and 25.3%. The latest quarter is within that range.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +1.0 percentage points on the year while gross margin changed +0.8 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years, 165% of Neurocrine Biosciences, Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $783 M of operating cash against $479 M of profit. After $34.0 M of spending on assets, $749 M was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Neurocrine Biosciences, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $101 M on assets over the last 3 years. Averaged over those years that is 1.2% of FY25 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $101 M over the last 3 years.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Neurocrine Biosciences, Inc.'s P/E is 24.7×, near the low end of its own history: it has been lower only 11% of the time. Its usual P/E (the middle reading) is 42.5×, over 4.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

Why the multiple is where it is: over the past year earnings per share moved +41.9% while the price moved +9.0%. Earnings did better than the price, which pulled the multiple down within its own range.

Where the price move came from: over 3 years the price moved +13.9% a year; about +54.3% a year came from earnings growth and about −40.4 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple.

Neurocrine Biosciences, Inc.'s business is growing steadily. Revenue, profit and EPS growth have stayed positive throughout, and ROCE is steady at 22.1%. This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: steady growth with healthy returns is how a business compounds over time.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.